R

RGEN

RGEN

UnknownUnknown

Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.

Insider Sentiment
Based on recent trading activity
11%Bearish
Buy/Sell Ratio1% buys
BearishBullish
RGEN Live QuoteReal-time
$170.29
$9.72(-5.40%)1M
Day Range$168.94 – $178.85
Open$173.69
Previous Close$172.67
Volume880.6K
Key Financials & Valuation
Fundamental balance sheet & market metrics
HEALTHCARE
Market Cap$11.04B
P/E Ratio (TTM)24.5
Forward P/E58.5
EPS (TTM)$-0.21
Price to Book5.0
Dividend Yield0.65%
Beta (Volatility)1.12
IndustryMEDICAL INSTRUMENTS & SUPPLIES
52-Week RangeCurrent: $170.29 (71%)
Low: $100.99High: $198.87
Wall Street Consensus
Strong Buy
Analyst Rating
4.8/ 5.0
Target Price
$203.21+35.5% upside

Insider Buys

2

$240K

Insider Sales

17

$29.51M

Total Volume

$29.75M

19 transactions

Net Activity

$29.27M

Net selling

Proprietary Ratings
Calculated from Form 4 transactions
25CONFIDENCE

Sentiment Rating

Moderate Distribution

CEO Conviction Index

Liquidating / Profit Taking

Key Drivers

  • •Heavy distribution: sales represent 99% of total transaction value.
  • •Minor cluster buying: 2 unique insiders purchased shares.
  • •CEO selling activity detected. Often driven by option expiration or diversification plans.
  • •Significant liquidation: total sale value exceeds $10M.
Score Methodology

The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:

  • +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
  • +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
  • +15CEO Buying: CEO committing own capital shows high conviction.
  • +10CFO Buying: CFO purchasing shares shows financial alignment.
Top Insiders
Most active traders
H
1

Hunt Anthony

Dir

0 buys6 sells

$21.26M total

L
2

Loeillot Olivier

CEO

0 buys7 sells

$7.69M total

B
3

Bylund James

COO

0 buys1 sells

$331K total

M
4

Madaus Martin D

Dir

1 buys0 sells

$202K total

G
5

Garland Jason K

CFO

0 buys2 sells

$186K total

Trading History
RGEN insider transactions from SEC Form 4 filings
DateInsiderTypeSharesPriceValueFiling

Oct 5, 2026

1 months ago

Loeillot Olivier

CEO

CEO
Sell5.5K$187.29$1.04M

Sep 24, 2026

1 months ago

Loeillot Olivier

CEO

CEO
Sell12.9K$190.00$2.46M

Sep 21, 2026

2 months ago

Loeillot Olivier

CEO

CEO
Sell5.4K$180.00$977K

Sep 4, 2026

2 months ago

Loeillot Olivier

CEO

CEO
Sell3.0K$165.90$504K

Aug 20, 2026

3 months ago

Loeillot Olivier

CEO

CEO
Sell5.4K$180.00$977K

Jul 16, 2026

4 months ago

Garland Jason K

CFO

CFO
Sell530$150.00$80K

Jun 25, 2026

4 months ago

Garland Jason K

CFO

CFO
Sell733$145.00$106K

Apr 21, 2026

7 months ago

Loeillot Olivier

CEO

CEO
Sell3.8K$140.00$536K

Dec 17, 2025

11 months ago

Dawes Karen A

Dir

Director
Sell275$161.00$44K

Nov 25, 2025

12 months ago

Loeillot Olivier

CEO

CEO
Sell7.0K$170.00$1.20M

Nov 18, 2025

12 months ago

Bylund James

COO

COO
Sell2.2K$151.21$331K

Nov 13, 2025

12 months ago

Hunt Anthony

Dir

Director
Sell20.0K$154.61$3.09M

Nov 12, 2025

12 months ago

Hunt Anthony

Dir

Director
Sell25.0K$156.88$3.92M

Sep 10, 2025

14 months ago

Hunt Anthony

Dir

Director
Sell29.1K$120.52$3.51M

Aug 8, 2025

15 months ago

Madaus Martin D

Dir

Director
Buy1.8K$112.13$202K

May 15, 2025

18 months ago

Hunt Anthony

Dir

Director
Sell26.4K$123.71$3.27M

Mar 17, 2025

20 months ago

Hunt Anthony

Dir

Director
Sell26.8K$152.51$4.08M

Mar 17, 2025

20 months ago

Pax Margaret

Dir

Director
Buy250$150.69$38K

Nov 21, 2024

24 months ago

Hunt Anthony

Dir

Director
Sell24.2K$139.67$3.39M
Sector & Industry Benchmarks
Unknown Comparison Overview
Industry Buy Conviction6%
RGEN Buy Conviction1%
Industry Rank#0 of 570
Volume Contribution0.2%
Total Industry Activity$16.44B

RGEN has an insider buy conviction of 1%, compared to the Unknown sector buy average of 6%.

Insider Trading Summary & Commentary
Automated executive transaction analysis for RGEN

Over the last 90 days, corporate insiders at RGEN (RGEN) engaged in a total of 19 transactions reported via SEC Form 4 filings. Among these, 2 were open-market purchases and 17 were sales. The total volume of insider trading reached $29.75M.

The net insider activity for RGEN shows a net selling bias of $29.27M. This activity represents a 1% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.

The most notable individual transaction was a Sale by Hunt Anthony (Dir), who traded 26.8K shares valued at $4.08M on Mar 17, 2025.

Live Market News & Developments
Aggregated real-time headlines for RGEN (RGEN)
6 updates

Repligen Corporation (RGEN) Stock Price, News, Quote & History

Yahoo! Finance Canada2d ago

Repligen Corporation (RGEN) stock price, news, quote and history

Yahoo Finance Singapore2d ago

Repligen Corporation (RGEN) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow

Seeking AlphaYesterday

Repligen Stock Price Forecast. Should You Buy RGEN?

StockInvest.us10d ago

Repligen (RGEN) Stock Looks Fairly Valued As Cash Flow Growth Matters

Yahoo Finance3d ago

RGEN Nov 2026 90.000 call (RGEN261120C00090000) interactive stock chart

Yahoo Finance UK14h ago

FAQs About RGEN Insider Trading

Answers to common questions regarding corporate filings and executive sentiment for RGEN.

Based on SEC Form 4 disclosures, the Insider Confidence Score for RGEN is currently 25/100, which reflects a moderate distribution bias. This calculation accounts for a total of 2 purchases and 17 sales by company executives over the last 90 days.

The CEO Conviction Index for RGEN is rated as "Liquidating / Profit Taking". Executive buying is typically a strong vote of confidence as C-level leaders have the most intimate knowledge of their firm's prospects. Officer selling, on the other hand, is often routine and does not automatically signal operational weakness.

No. Insider tracking is a highly informative technical signal that indicates executive sentiment, but it should not be the sole basis for a transaction. Investors should combine this filing analysis with company financials, sector trends, and risk management criteria.